以波洛克萨默为基础的生物材料作为药物战略,以提高伊弗梅克的性能
Belén Alejandra Mezzano1, Maria Soledad Bueno1, Valeria Cintia Fuertes2
1Departamento de Ciencias Farmacéuticas, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Unidad de Investigación y Desarrollo en Tecnología Farmacéutica (UNITEFA) CONICET-UNC, Córdoba X5000HUA, Argentina.
Pharmaceutics
|September 27, 2025
概括
波洛克萨默407固体分散剂显著增强了ivermectin的作用.
科学领域:
- 制药科学 制药科学
- 材料科学 材料科学 材料科学
- 生物材料工程 生物材料工程
背景情况:
- 波洛克萨默是具有药物输送潜力的多功能生物材料.
- 增强生物制药性质是poloxamers的一个关键应用.
- 由于其水溶性较差,可以限制ivermectin的生物可用性.
研究的目的:
- 使用Poloxamer 407.7设计和优化ivermectin的固体分散剂.
- 为了研究合成变量对poloxamer行为和ivermectin特性的影响.
- 评估开发的固体分散物的增强生物制药特性.
主要方法:
- 用于固体分散制备的融合方法.
- 合成参数的系统变化:聚合物比例,冷却梯度和温度.
- 包括可溶性,溶解和体外释放研究在内的综合性表征.
主要成果:
- 波洛克萨默407和ivermectin之间的兼容性得到证实.
- 冷却速度显著影响了Poloxamer的自组装和药物捕获.
- 优化的1:1 w/w ivermectin:poloxamer 407固体分散显示出水溶性增加了1600倍.
- 纳米粒子大小和降低的结晶性有助于增强溶解和药物释放.
结论:
- 波洛克萨默407固体分散为改善ivermectin生物可用性提供了一个有希望的策略.
- 合成过程,特别是冷却速度,对于优化固体分散性能至关重要.
- 这些配方代表了一种可行的替代品,可以增强像ivermectin这样可溶性较差的药物的输送.
相关概念视频
01:27Bioavailability Enhancement: Drug Permeability Enhancement
186
Body:After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt...
186
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
200
Body:Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
200
01:16Bioavailability Enhancement: Drug Solubility Enhancement
221
Body:Bioavailability is a critical factor in determining a drug's effectiveness. It refers to the proportion of a drug that enters the circulation when introduced into the body and is, as a result, able to have an active effect. Enhancing bioavailability is essential for drugs with poor solubility, as it can significantly impact their therapeutic efficacy. Various methods are employed to increase the solubility of drugs, thereby enhancing their bioavailability.Micronization and nanonization are...
221
01:28Factors Influencing Drug Absorption: Pharmaceutical Parameters
403
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
403
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
151
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
151
01:21Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism
673
Polymorphism refers to the existence of a drug substance in multiple crystalline forms, known as polymorphs. Recently, this term has been expanded to include solvates (forms containing a solvent), amorphous forms (non-crystalline forms), and desolvated solvates (forms from which the solvent has been removed).
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
673